The idea of BH3 mimetics as promising anticancer drugs is inspired by the conclusion that a great deal of cancers rely on BCL-2 family proteins and that the interaction between these proteins occurs through specific BH domains (Oltersdorf et al., 2005; Soderquist and Eastman, 2016). The gene discussed is BCL2; the disease is cancer.